Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children24810.24287/1726-1708-2019-18-2-83-91ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИBrentuximab vedotin in the treatment of children and adolescents with refractory and relapsed Hodgkin's lymphomaБрентуксимаб ведотин в лечении рецидивирующей и рефрактерной лимфомы Ходжкина у детей и подростковhttps://orcid.org/0000-0003-4072-601XKozlovA. V.КозловА. В.
Russian Federation

Andrey V. Kozlov, senior researcher.

197022, Saint-Petersburg, Tolstoy st., 6/8.

Козлов Андрей Вадимович, канд. мед. наук, ст. науч. сотрудник.

197022, Санкт-Петербург, ул. Льва Толстого, 6/8/

kozlovandrew@list.ruhttps://orcid.org/0000-0002-3818-6213KazantzevI. V.КазанцевИ. В.
Russian Federation
https://orcid.org/0000-0002-5979-9182IukhtaT. V.ЮхтаТ. В.
Russian Federation
https://orcid.org/0000-0002-2296-0358TolkunovaP. S.ТолкуноваП. С.
Russian Federation
https://orcid.org/0000-0003-2905-8209GevorgianA. G.ГеворгянА. Г.
Russian Federation
https://orcid.org/0000-0002-4056-050XLepikK. V.ЛепикК. В.
Russian Federation
https://orcid.org/0000-0003-1454-8045BorzenkovaE. S.БорзенковаЕ. С.
Russian Federation
https://orcid.org/0000-0002-3881-4486ZaljalovYu. R.ЗаляловЮ. Р.
Russian Federation
https://orcid.org/0000-0001-5991-0066BotinaA. V.БотинаА. В.
Russian Federation
https://orcid.org/0000-0002-9191-5091BaikovV. V.БайковВ. В.
Russian Federation
https://orcid.org/0000-0002-9605-485XMorozovaE. V.МорозоваЕ. В.
Russian Federation
https://orcid.org/0000-0002-2913-047XMikhailovaN. B.МихайловаН. Б.
Russian Federation
https://orcid.org/0000-0003-2594-7703ZubarovskayaL. S.ЗубаровскаяЛ. С.
Russian Federation
https://orcid.org/0000-0002-1235-4530AfanasyevB. V.АфанасьевБ. В.
Russian Federation
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of Saint-PetersburgФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова», Научно-исследовательский институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой2906201918283912906201929062019Copyright ©; 2019, «D. Rogachev NMRCPHOI»Copyright ©; 2019, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2019«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/248

Children and adolescents with refractory or relapsed Hodgkin's lymphoma (R-R HL) have unfavorable prognosis if ≥ 3 lines of therapies have to be used. New strategies based on innovative approaches are crucial for this group of patients. Nowadays immunotherapy for oncological diseases is the most promising and actively developing area. Brentuximab vedotin (BV) is efficient in adults with HL. Data in children are limited to pilot studies that are focused on response to treatment without analysis of survival. The present study demonstrates experience of Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation (First Pavlov State Medical University of Saint-Petersburg) in the management of heavily pretreated (median number of prior lines – 4) children and adolescents with R-R HL. The study was approved by the Independent Ethics Committee of the Raisa Gorbacheva Memorial Research Institute of Children's Oncology, Hematology and Transplantation. Brentuximab vedotin was administered to 34 patients. Overall response was achieved in 71% (complete response – 29%, partial response – 42%). Long-term progression free and overall survival were 24 and 54%, respectively.

После проведения трех и более линий терапии у детей и подростков с рецидивирующим и рефрактерным течением лимфомы Ходжкина прогноз становится неблагоприятным. В связи с этим требуется поиск новых, основанных на иных принципах, методов лечения данной группы пациентов. В онкологии активно и успешно развивается иммунотерапия. У взрослых с лимфомой Ходжкина хорошо зарекомендовал себя таргетный препарат брентуксимаб ведотин. Опыт использования его у детей ограничен небольшими пилотными исследованиями, результаты которых отражают частоту ответа на проводимую терапию и не затрагивают принципиальные вопросы выживаемости без прогрессирования и общей выживаемости. В представленной работе продемонстрирован опыт НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой Первого Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова по ведению значительно предлеченных детей и подростков (медиана линий терапии – 4) с рецидивирующим и рефрактерным течением лимфомы Ходжкина. Исследование поддержано Независимым этическим комитетом НИИ ДОГиТ им. Р.М. Горбачевой. Всего брентуксимабом ведотином пролечены 34 пациента. Общий ответ достигнут в 71% случаев (полный ответ – в 29%; частичный – в 42% случаев); долгосрочные выживаемость без прогрессирования и общая выживаемость составили 24 и 54% соответственно.

Hodgkin's lymphomarefractoryrelapsedBrentuximab vedotinadolescentsсhildrenлимфома Ходжкинарецидивирующаярефрактернаябрентуксимаб ведотинподросткидети1. Harris R.E., Termuhlen A.M., Smith L.M., Lynch J., Henry M.M., Perkins S.L., et al. Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962. Biol Blood Marrow Transplant 2011 Feb; 17 (2): 249–58.Harris R.E., Termuhlen A.M., Smith L.M., Lynch J., Henry M.M., Perkins S.L., et al. Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962. Biol Blood Marrow Transplant 2011 Feb; 17 (2): 249–58.2. Schellong G., Dorffel W., Claviez A., Körholz D., Mann G., Scheel-Walter H.G., et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181–9.Schellong G., Dorffel W., Claviez A., Körholz D., Mann G., Scheel-Walter H.G., et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181–9.3. Giulino-Roth L., O'Donohue T., Chen Z., Trippett T.M., Klein E., Kernan N.A., et al. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma 2017 Nov; 29: 1–10.Giulino-Roth L., O'Donohue T., Chen Z., Trippett T.M., Klein E., Kernan N.A., et al. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma 2017 Nov; 29: 1–10.4. Satwani P., Ahn K.W., Carreras J., Abdel-Azim H., Cairo M.S., Cashen A., et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 2015; 50: 1416–23.Satwani P., Ahn K.W., Carreras J., Abdel-Azim H., Cairo M.S., Cashen A., et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 2015; 50: 1416–23.5. Куличкина Н.С., Беляева Е.С., Менткевич Г.Л., Бояршинов В.К., Левашов А.С., Глеков И.В., Попа А.В. Лечение рецидивов и рефрактерных форм лимфомы Ходжкина у детей. Клиническая онкогематология 2016; 9 (1): 13–21.Куличкина Н.С., Беляева Е.С., Менткевич Г.Л., Бояршинов В.К., Левашов А.С., Глеков И.В., Попа А.В. Лечение рецидивов и рефрактерных форм лимфомы Ходжкина у детей. Клиническая онкогематология 2016; 9 (1): 13–21.6. Kobos R., Terry W. Advances in therapies for non-Hodgkin lymphoma in children. ASH Education Book 2015 Dec 5; 1: 522–8.Kobos R., Terry W. Advances in therapies for non-Hodgkin lymphoma in children. ASH Education Book 2015 Dec 5; 1: 522–8.7. Leoncini L., Ambrosio M.R., Lazzi S., Rocca B.J., Tosi P. CD30 expression in lymphoid neoplasms: from diagnostic marker to target of therapy. DCTH 2013; 4: 279–300.Leoncini L., Ambrosio M.R., Lazzi S., Rocca B.J., Tosi P. CD30 expression in lymphoid neoplasms: from diagnostic marker to target of therapy. DCTH 2013; 4: 279–300.8. Katz J., Janik J.E., Younes A. Bretuximab Vedotin. Clinical Cancer. Research 2011; 17 (20): 6428–36.Katz J., Janik J.E., Younes A. Bretuximab Vedotin. Clinical Cancer. Research 2011; 17 (20): 6428–36.9. Мякова Н.В., Евстратов Д.А., Абрамов Д.С., Коновалов Д.М., Пшонкин А.В., Литвинов Д.В. Применение брентуксимаба ведотина у детей и подростков с лимфомой Ходжкина и анапластической крупноклеточной лимфомой – обзор литературы и собственные наблюдения. Онкогематология 2016; 11: 8–14.Мякова Н.В., Евстратов Д.А., Абрамов Д.С., Коновалов Д.М., Пшонкин А.В., Литвинов Д.В. Применение брентуксимаба ведотина у детей и подростков с лимфомой Ходжкина и анапластической крупноклеточной лимфомой – обзор литературы и собственные наблюдения. Онкогематология 2016; 11: 8–14.10. Locatelli F., Mauz-Koerholz C., Neville K., Llort A., Beishuizen A., Daw S., et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol 2018 Oct; 5 (10): e450-e461. Doi: 10.1016/S2352-3026(18)30153-4Locatelli F., Mauz-Koerholz C., Neville K., Llort A., Beishuizen A., Daw S., et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol 2018 Oct; 5 (10): e450-e461. Doi: 10.1016/S2352-3026(18)30153-411. Cole P.D., McCarten K.M., Pei Q., Spira M., Metzger M.L., Drachtman R.A., et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol 2018 Sep; 19 (9): 1229–38. Doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16Cole P.D., McCarten K.M., Pei Q., Spira M., Metzger M.L., Drachtman R.A., et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol 2018 Sep; 19 (9): 1229–38. Doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 1612. Gulati N., Boulad F., Cancio M.I., Curran K.J., Jackson K., Kernan N., et al. Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma. Blood 2017; 130: 5172.Gulati N., Boulad F., Cancio M.I., Curran K.J., Jackson K., Kernan N., et al. Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma. Blood 2017; 130: 5172.13. Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30 (18): 2183–9.Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30 (18): 2183–9.14. Zinzani P.L., Viviani S., Anastasia A., Vitolo U., Luminari S., Zaja F., et al. Brentuximab vedotin in relapsed/ refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013 Aug; 98 (8): 1232–6. Doi: 10.3324/haematol.2012.083048 Epub 2013 May 3Zinzani P.L., Viviani S., Anastasia A., Vitolo U., Luminari S., Zaja F., et al. Brentuximab vedotin in relapsed/ refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013 Aug; 98 (8): 1232–6. Doi: 10.3324/haematol.2012.083048 Epub 2013 May 315. Gibb A., Jones C., Bloor A., Kulkarni S., Illidge T., Linton K., Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013 Apr; 98 (4): 611–4. Doi: 10.3324/haematol.2012.069393 Epub 2012 Oct 12.Gibb A., Jones C., Bloor A., Kulkarni S., Illidge T., Linton K., Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013 Apr; 98 (4): 611–4. Doi: 10.3324/haematol.2012.069393 Epub 2012 Oct 12.16. Cassaday R.D., Fromm J., Cowan A.J., Libby E.B. III, Philip M., Behnia S., et al. Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/ Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. Blood 2016; 128: 1834.Cassaday R.D., Fromm J., Cowan A.J., Libby E.B. III, Philip M., Behnia S., et al. Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/ Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. Blood 2016; 128: 1834.17. Michallet A.S., Guillermin Y., Deau B., Lebras L., Harel S., Amorin S., et al. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica 2015 Jul; 100 (7): e269–71. Doi: 10.3324/haematol.2015.124784 Epub 2015 Apr 3.Michallet A.S., Guillermin Y., Deau B., Lebras L., Harel S., Amorin S., et al. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica 2015 Jul; 100 (7): e269–71. Doi: 10.3324/haematol.2015.124784 Epub 2015 Apr 3.18. LaCasce A.S., Gregory B.R., Sawas A., Caimi P., Agura E., Matous J., et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018 Jul 5; 132 (1): 40–8. Doi: 10.1182/blood-2017-11-815183 Epub 2018 Apr 27.LaCasce A.S., Gregory B.R., Sawas A., Caimi P., Agura E., Matous J., et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018 Jul 5; 132 (1): 40–8. Doi: 10.1182/blood-2017-11-815183 Epub 2018 Apr 27.19. Herrera A.F., Moskowitz A.J., Bartlett N.L., Vose J.M., Ramchandren R., Feldman T.A., et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018 Mar 15; 131 (11): 1183–94.Herrera A.F., Moskowitz A.J., Bartlett N.L., Vose J.M., Ramchandren R., Feldman T.A., et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018 Mar 15; 131 (11): 1183–94.20. Moskowitz C.H., Nademanee A., Masszi T., Agura E., Holowiecki J., Abidi M.H., et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2015 May 9; 385 (9980), 1853–62.Moskowitz C.H., Nademanee A., Masszi T., Agura E., Holowiecki J., Abidi M.H., et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2015 May 9; 385 (9980), 1853–62.21. Bazarbachi A., Boumendil A., Finel H., Mohty M., Castagna L., Blaise D., et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer 2019; 125 (1): 90–8Bazarbachi A., Boumendil A., Finel H., Mohty M., Castagna L., Blaise D., et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer 2019; 125 (1): 90–822. Михайлова Н.Б., Борзенкова Е.С., Иванова М.О., Кондакова Е В., Попова М.О., Моисеев И.С. и др. Эффективность и безопасность брентуксимаба как препарата "спасения" для подготовки к алло-ТГСК больных сd30+ лимфопролиферативными заболеваниями. Гематология и трансфузиология 2014; 59, S1: 105.Михайлова Н.Б., Борзенкова Е.С., Иванова М.О., Кондакова Е В., Попова М.О., Моисеев И.С. и др. Эффективность и безопасность брентуксимаба как препарата "спасения" для подготовки к алло-ТГСК больных сd30+ лимфопролиферативными заболеваниями. Гематология и трансфузиология 2014; 59, S1: 105.23. Bazarbachi A., Boumendil A., Finel H., Mohty M., Castagna L., Peggs K.S., et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol 2018 Apr; 181 (1): 86–96.Bazarbachi A., Boumendil A., Finel H., Mohty M., Castagna L., Peggs K.S., et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol 2018 Apr; 181 (1): 86–96.24. Tsirigotis P., Danylesko I., Gkirkas K., Shem-Tov N., Yerushalmi R., Stamouli M., et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016 Oct; 51 (10): 1313–7.Tsirigotis P., Danylesko I., Gkirkas K., Shem-Tov N., Yerushalmi R., Stamouli M., et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016 Oct; 51 (10): 1313–7.25. Dozzo M., Zaja F., Volpetti S., Sperotto A., Magli A., Fanin R. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. American Journal of Hematology 2015; 90 (4): E73.Dozzo M., Zaja F., Volpetti S., Sperotto A., Magli A., Fanin R. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. American Journal of Hematology 2015; 90 (4): E73.26. Pro B., Advani R, Brice P., et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017; 130 (25): 2709–17.Pro B., Advani R, Brice P., et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017; 130 (25): 2709–17.27. Smith S.M., Burns L.J., van Besien K., Lerademacher J., He W., Fenske T.S., et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31 (25): 3100–9.Smith S.M., Burns L.J., van Besien K., Lerademacher J., He W., Fenske T.S., et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31 (25): 3100–9.28. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., et al. Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27): 3059–68. [PMC free article] [PubMed].Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., et al. Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27): 3059–68. [PMC free article] [PubMed].